Gerresheimer CEO dubs weight-loss drugs a meaningful positive catalyst
Dietmar Siemssen – the chief executive of Gerresheimer AG (ETR: GXI) expects strong demand for weight-loss drugs to be a meaningful tailwind for his company. Weight-loss drugs to boost $GXI revenue growth Siemssen expects supply of vials, syringes, cartridges, and autoinjectors to makers of GLP-1 drugs to account for about 4.0% of revenue growth per […]